Zomedica Corp
AMEX:ZOM
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.12
0.2198
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ZOM stock under the Base Case scenario is 0.13 USD. Compared to the current market price of 0.13 USD, Zomedica Corp is Overvalued by 3%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Zomedica Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ZOM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Zomedica Corp
Balance Sheet Decomposition
Zomedica Corp
Current Assets | 87.3m |
Cash & Short-Term Investments | 76.9m |
Receivables | 2.4m |
Other Current Assets | 8m |
Non-Current Assets | 126.8m |
Long-Term Investments | 966k |
PP&E | 27.4m |
Intangibles | 97.2m |
Other Non-Current Assets | 1.3m |
Current Liabilities | 8.1m |
Accounts Payable | 7m |
Accrued Liabilities | 728k |
Other Current Liabilities | 293k |
Non-Current Liabilities | 3.2m |
Other Non-Current Liabilities | 3.2m |
Earnings Waterfall
Zomedica Corp
Revenue
|
26.7m
USD
|
Cost of Revenue
|
-8.1m
USD
|
Gross Profit
|
18.6m
USD
|
Operating Expenses
|
-56.9m
USD
|
Operating Income
|
-38.3m
USD
|
Other Expenses
|
-23.9m
USD
|
Net Income
|
-62.2m
USD
|
Free Cash Flow Analysis
Zomedica Corp
USD | |
Free Cash Flow | USD |
ZOM Profitability Score
Profitability Due Diligence
Zomedica Corp's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Zomedica Corp's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
ZOM Solvency Score
Solvency Due Diligence
Zomedica Corp's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Zomedica Corp's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZOM Price Targets Summary
Zomedica Corp
According to Wall Street analysts, the average 1-year price target for ZOM is 0.26 USD with a low forecast of 0.25 USD and a high forecast of 0.26 USD.
Dividends
Current shareholder yield for ZOM is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ZOM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 85 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's Diagnostics segment consists of TRUFORMA products. Its Therapeutics segment consists of PulseVet and Assisi products. Its TRUFORMA Bulk Acoustic Wave (BAW) point-of-care diagnostic platform is marketed with full diagnostic and thyroid panels for dogs and cats that include the only assays of these types available at the point of care to test for feline optimized TSH, endogenous ACTH, Free T4, and quantitative cortisol, along with a total T4 assay. The VetGuardian is its zero-touch vital signs remote monitoring system that enables contact-free, continuous monitoring of a pet's vital signs. The PulseVet is its electrohydraulic shockwave therapy platform. Its Assisi Loop line of products treats pain and inflammation through the delivery of targeted pulsed electromagnetic field focused energy (tPEMF).
Contact
IPO
Employees
Officers
The intrinsic value of one ZOM stock under the Base Case scenario is 0.13 USD.
Compared to the current market price of 0.13 USD, Zomedica Corp is Overvalued by 3%.